Targeting 6-phosphofructo-2-kinase (PFKFB3) as an immunotherapeutic strategy.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Clinical Oncology

• Publication date

  2016-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2016.34.15_SUPPL.E14548
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• PFKFB3 Regulates Chemoresistance, Metastasis and Stemness via IAP Proteins and the NF-κB Signaling Pathway in Ovarian Cancer

  2022cites this paper
• Nuances of PFKFB3 Signaling in Breast Cancer.

  2022cites this paper
• Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer.

  2022cites this paper
• A potent PGK1 antagonist reveals PGK1 regulates the production of IL-1β and IL-6

  2022cites this paper
• Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies

  2021cites this paper
• Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism

  2021cites this paper
• Navigating metabolic pathways to enhance antitumour immunity and immunotherapy

  2019cites this paper
• Roles of PFKFB3 in cancer

  2017cites this paper
• A bio-inspired computing model for ovarian carcinoma classification and oncogene detection

  2015cites this paper